Compare Stocks → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ABEONASDAQ:CAPRNASDAQ:CNCENASDAQ:COCPNASDAQ:NEPT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$3.19+0.6%$7.37$2.83▼$9.01$87.25M1.49432,179 shs1.10 million shsCAPRCapricor Therapeutics$5.15+2.2%$5.58$2.68▼$8.22$162.23M3.99299,000 shs387,928 shsCNCEConcert Pharmaceuticals$8.37$8.37$2.66▼$8.55$401.26M0.522.97 million shsN/ACOCPCocrystal Pharma$1.51-3.2%$1.49$1.33▼$3.29$15.36M1.3413,189 shs1,699 shsNEPTNeptune Wellness Solutions$0.39$0.19▼$28.00$906K2.19462,687 shs2.25 million shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-7.04%-60.03%-57.16%-33.40%-2.76%CAPRCapricor Therapeutics+4.56%-9.19%-23.98%+22.93%+28.24%CNCEConcert Pharmaceuticals0.00%0.00%0.00%0.00%0.00%COCPCocrystal Pharma-3.97%+4.90%0.00%-3.23%-40.48%NEPTNeptune Wellness Solutions0.00%0.00%0.00%-57.45%-99.25%Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABEOAbeona Therapeutics3.6381 of 5 stars3.51.00.04.51.61.70.6CAPRCapricor Therapeutics1.078 of 5 stars3.50.00.00.02.30.80.6CNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACOCPCocrystal Pharma2.8475 of 5 stars3.55.00.00.00.71.71.3NEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics3.00Buy$36.001,028.53% UpsideCAPRCapricor Therapeutics3.00Buy$24.00366.02% UpsideCNCEConcert PharmaceuticalsN/AN/AN/AN/ACOCPCocrystal Pharma3.00Buy$10.00562.25% UpsideNEPTNeptune Wellness SolutionsN/AN/AN/AN/ACurrent Analyst RatingsLatest CNCE, COCP, NEPT, ABEO, and CAPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2024CAPRCapricor TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.004/23/2024ABEOAbeona TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$36.004/4/2024COCPCocrystal PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/20/2024COCPCocrystal PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/1/2024CAPRCapricor TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M24.93N/AN/A$0.60 per share5.32CAPRCapricor Therapeutics$25.18M6.44N/AN/A$0.73 per share7.05CNCEConcert Pharmaceuticals$32.58M12.32N/AN/A$3.24 per share2.58COCPCocrystal PharmaN/AN/AN/AN/A$2.59 per shareN/ANEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$54.19M-$2.58N/AN/AN/AN/A-280.58%-76.90%5/9/2024 (Estimated)CAPRCapricor Therapeutics-$22.29M-$0.87N/A42.92N/A-88.52%-299.67%-45.54%5/9/2024 (Estimated)CNCEConcert Pharmaceuticals-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/ACOCPCocrystal Pharma-$17.98M-$1.99N/AN/AN/AN/A-59.62%-54.62%5/20/2024 (Estimated)NEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%7/15/2024 (Estimated)Latest CNCE, COCP, NEPT, ABEO, and CAPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023COCPCocrystal Pharma-$0.57-$0.44+$0.13-$0.44N/AN/A3/18/2024Q4 2023ABEOAbeona Therapeutics-$0.51-$0.64-$0.13-$0.64N/AN/A2/29/2024Q4 2023CAPRCapricor Therapeutics-$0.23-$0.02+$0.21-$0.02$5.80 million$12.09 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/ACAPRCapricor TherapeuticsN/AN/AN/AN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/AN/ACOCPCocrystal PharmaN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona TherapeuticsN/A4.154.15CAPRCapricor TherapeuticsN/A1.631.63CNCEConcert PharmaceuticalsN/A9.039.03COCPCocrystal PharmaN/A8.928.92NEPTNeptune Wellness SolutionsN/A0.230.10OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%CAPRCapricor Therapeutics21.68%CNCEConcert Pharmaceuticals70.63%COCPCocrystal Pharma6.72%NEPTNeptune Wellness Solutions14.44%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics5.30%CAPRCapricor Therapeutics12.00%CNCEConcert Pharmaceuticals11.33%COCPCocrystal Pharma25.06%NEPTNeptune Wellness Solutions5.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona TherapeuticsN/A27.35 million25.91 millionOptionableCAPRCapricor TherapeuticsN/A31.50 million27.72 millionOptionableCNCEConcert Pharmaceuticals6447.94 million42.51 millionOptionableCOCPCocrystal Pharma1210.17 million7.62 millionNot OptionableNEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionableCNCE, COCP, NEPT, ABEO, and CAPR HeadlinesSourceHeadlineNeptune Wellness Solutions (NASDAQ:NEPT) Now Covered by Analysts at StockNews.comamericanbankingnews.com - April 16 at 2:22 AMNeptune prepared to take legal action against property owner of the homeless encampmentmsn.com - April 9 at 2:18 PMCity of Neptune Beach unveils new water tower designmsn.com - April 7 at 1:48 PMGunbattle between Haitian police and gangs paralyzes area near National Palacesaratogian.com - April 2 at 1:45 AMThe Wellness Innovation Summit at the Knoxville Convention Center Saturday, April 6thwate.com - April 1 at 10:44 AMSNAPSHOT: Construction supervisor credits BOCES with building him a solid foundation for his futuresaratogian.com - April 1 at 10:44 AMWellness Wednesday – Focusing on Cardiovascular Healthnwahomepage.com - March 28 at 6:30 PMFood Encapsulation Market Industry Chain Information, Emerging Market Regions (2024-2032)taiwannews.com.tw - March 28 at 6:30 PMSNAPSHOT: The Bunker celebrates opening of newest location in Saratoga Springssaratogian.com - March 25 at 8:40 AMSNAPSHOT: Capital Region BOCES event will link students to employers and recruiterssaratogian.com - March 24 at 9:05 AMKingdom Wellness & Dispensary opens new retail locationwestsidenewsny.com - March 18 at 12:39 PMWellness expo promotes better health within Black familiesksdk.com - March 17 at 8:17 PMRooted Wellness celebrates grand openinglowellsun.com - March 15 at 8:16 PMClinton to host Mayor's Wellness Program on Saturday, March 23newjerseyhills.com - March 15 at 3:15 PMYour Weekly Horoscopes: March 17 to 23, 2024purewow.com - March 15 at 12:13 AMHealthwise Wellness hosts clinic open housearkansasonline.com - March 13 at 7:38 AMSouthwell Center for Healing and Wellness to permanently closemsn.com - March 12 at 12:26 AMNeptune Software: 'Environmental Supply Chains - You Don't Need to Sacrifice Profitability to Act Sustainably'tmcnet.com - March 11 at 2:25 PMNeptune Wellness Solutions Inc.wsj.com - March 9 at 8:59 AMNeptune Wellness appoints Michael De Geus as interim president, CEOmsn.com - March 8 at 9:40 AMNeptune Appoints Interim President and CEO and Interim COOaccesswire.com - March 8 at 8:30 AMNeptune Wellness to be delisted from Nasdaqinvesting.com - March 8 at 12:42 AMTop Marijuana Stocks For Trading Today 2024marijuanastocks.com - March 6 at 9:06 AMNeptune Announces Decision of Nasdaq Hearings Panel To Delist Common Sharesaccesswire.com - March 6 at 8:30 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAbeona TherapeuticsNASDAQ:ABEOAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Capricor TherapeuticsNASDAQ:CAPRCapricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Concert PharmaceuticalsNASDAQ:CNCEConcert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.Cocrystal PharmaNASDAQ:COCPCocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Neptune Wellness SolutionsNASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.